• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi 2022 Projects of the Year recognize partners and colleagues for their work in developing new treatments for leishmaniasis

3 Oct 2022

The Drugs for Neglected Diseases initiative (DNDi) is very pleased to announce the two 2022 Projects of the Year, which recognize DNDi R&D teams and key partners for outstanding progress in the areas of pre-clinical and clinical research. Nominated by the DNDi Scientific Advisory Committee and selected by the DNDi Executive Board, the 2022 awards recognize two projects from among the more than 50 active projects in DNDi’s R&D portfolio. 

The partners and staff who collaborate on the 2022 Projects of the Year were celebrated during the WorldLeish7 scientific conference in Cartagena, Colombia, during a special joint convening of the redeLEISH and LEAP platforms, in August 2022.

CpG-D35 project for cutaneous leishmaniasis – 2022 Project of the Year in pre-clinical evaluation

CpG-D35 is being developed as a combination therapy for the treatment of complicated cutaneous leishmaniasis and potentially for post-kala-azar dermal leishmaniasis (PKDL) in partnership with Ajinomoto Bio-Pharma Services (GeneDesign, Inc.) and the University of Tokyo. 

Leishmania parasites can persist in host cells by evading or exploiting immune mechanisms. Modulating the immune response with CpG oligonucleotides may improve the effectiveness of chemotherapies in complicated forms of the disease. This project aims to produce an immunomodulator to stimulate the innate immune system and fight parasitic infection as an adjunct to drug therapy. 

In 2021, the CpG-D35 clinical programme progressed to first-in-human clinical trials with a single ascending dose study in healthy volunteers initiated and completed in the UK. Overall, CpG-D35 was found to be well tolerated and safe, and none of the criteria for stopping dose escalation were met. Based on these results, plans are underway to progress to a multiple ascending dose study in patients with cutaneous leishmaniasis in 2022.

Miltefosine + paromomycin combination for visceral leishmaniasis – 2022 Project of the Year in clinical research

Since 2010, the first-line treatment for visceral leishmaniasis in Eastern Africa has been a 17-day sodium stibogluconate plus paromomycin (SSG+PM) combination therapy. It is an improvement over the previous 30-day SSG monotherapy, but the treatment is still lengthy and painful, requiring patients to be hospitalized, and has potential toxic side effects. 

Based on the good efficacy of the miltefosine and paromomycin (MF+PM) combination therapy in South Asia, DNDi and AfriKADIA consortium partners conducted a Phase III clinical trial in Ethiopia, Kenya, Sudan, and Uganda to assess the safety and efficacy of miltefosine plus paromomycin (MF+PM) as an alternative to the standard of care in Eastern Africa. 

The study was completed in 2021 and results published last week showed that the MF+PM combination therapy was as effective as SSG+PM in adults and children but with fewer injections, a shorter treatment duration, and no risk of the potential life-threatening toxicity associated with SSG. MF+PM also reduced the risk of subsequent post-kala azar dermal leishmaniasis, which is a source of ongoing visceral leishmaniasis transmission in communities.   

Based on the evidence that it is an equally effective but more patient-friendly treatment, we will disseminate the study results with WHO and countries in East Africa for MF+PM to be adopted  as an alternative therapy for visceral leishmaniasis.

‘These two projects represent the significant investments we are making in leishmaniasis. In recent months, DNDi and partners have delivered a number of new treatments using existing medicines for leishmaniasis, while continuing to advance promising new chemical entities through our research and development portfolio,’ said Dr Laurent Fraisse, Director of R&D, DNDi. ‘My heartfelt congratulations and thanks to our partners and DNDi teams for their valuable work and steady commitment to delivering medical innovation for neglected patients.’ 

Read more about cutaneous leishmaniasis

Read more about visceral leishmaniasis

Clinical trials Translational research Cutaneous leishmaniasis Visceral leishmaniasis

Read, watch, share

Loading...
Videos
20 May 2025

The Children of the Sierra

Statements
19 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Woman walking in a laboratory
Press releases
23 Apr 2025

DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License